Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein.

Literature DB >> 618993

Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein.

Abstract

A method for the assay of human plasma prekallikrein in which a chromogenic synthetic tripeptide, PPAN, is used as a substrate for kallikrein is described. The conversion of prekallikrein to kallikrein is achieved by cold activation (0 degrees C) with water-soluble dextran sulfate. Conditions for obtaining optimal amounts of free kallikrein with respect to concentration of dextran sulfate, activation time, inhibitors (C-1-inactivator), and requirement of factor XII have been determined. The activation procedure is compared to other known procedures. The assay system was worked out for pooled normal plasma and is applicable to any plasma sample not liable to unwanted preactivation or incomplete inactivation, as revealed by control experiments. A survey in 15 apparently health individuals showed a mean activity of 476 +/- 58 (S.D.) mU/ml with a range of 385 to 586 mU/ml.

Entities: Chemical Gene Species

Mesh：

Substances：

Year: 1978 PMID： 618993

Source DB: PubMed Journal: J Lab Clin Med ISSN： 0022-2143

Keyword Cloud
Cited

14 in total

1. Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children.

Authors: James A MacKenzie; Kristen A Roosa; Brooks B Gump; Amy K Dumas; Kestutis G Bendinskas
Journal: Appl Physiol Nutr Metab Date: 2010-08 Impact factor: 2.665

2. A specific inhibitor of mammalian kallikrein, Phe-Phe-Arg-chloromethyl ketone, inhibits the production of vasoactive substances from trout plasma by kallikrein and blocks endogenous kallikrein-like activity in trout gills.

Authors: D W Lipke; K R Olson
Journal: Fish Physiol Biochem Date: 1992-12 Impact factor: 2.794

Review 3. Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors: A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal: Clin Rev Allergy Immunol Date: 1998 Impact factor: 8.667

4. Augmented plasma and tissue kallikrein like activity in synovial fluid of patients with inflammatory articular diseases.

Authors: N Volpe-Júnior; E A Donadi; I F Carvalho; M L Reis
Journal: Inflamm Res Date: 1996-04 Impact factor: 4.575

5. The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate. The effect of the Mr of the activating polyanion.

Authors: M Silverberg; S V Diehl
Journal: Biochem J Date: 1987-12-15 Impact factor: 3.857

Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein.

1. Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children.

2. A specific inhibitor of mammalian kallikrein, Phe-Phe-Arg-chloromethyl ketone, inhibits the production of vasoactive substances from trout plasma by kallikrein and blocks endogenous kallikrein-like activity in trout gills.

Review 3. Bradykinin formation. Plasma and tissue pathways and cellular interactions.

4. Augmented plasma and tissue kallikrein like activity in synovial fluid of patients with inflammatory articular diseases.

5. The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate. The effect of the Mr of the activating polyanion.

Review 6. Surface-mediated defense reactions. The plasma contact activation system.

7. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma.

8. Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.

9. Induction of proteolytic activity in serum by treatment with anionic detergents and organic solvents.

10. Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.